melanotan peptide 2 II (MT-II) Therapy Melanotan-II (MT-2) - Research Peptide

Benvenga S

Effect of Allium macrostemon on a rat model of depression studied by using plasma lipid and acylcarnitine profiles from liquid chromatography/mass spectrometry

Understanding your genetic profile helps optimize your GLP-1 protocol without guesswork or unnecessary add-ons

Inborn errors Congenital defects involve enzyme deficiencies in the carnitine transport or metabolic pathways, such as CPT II deficiency, which affects the function of the carnitine transporter CPT II and leads to impaired fatty acid -oxidation, and CACT deficiency, which affects the function of the carnitine transporter CACT and results in carnitine shuttle dysfunction